Honors Recognize BostonGene’s Platforms for Accelerating Trial Design, Improving Patient Selection and De-Risking Precision Medicine Outcomes at Scale
BostonGene, developer of the leading AI model for tumor and immune biology, today announced that it has been recognized as the Overall Winner in the 2026 Artificial Intelligence Excellence Awards by the Business Intelligence Group. The global program named BostonGene an Outstanding Organization, while simultaneously awarding top product honors for its multimodal AI platform.
In active development programs conducted with global pharmaceutical partners, BostonGene has helped accelerate translational research, strengthen biomarker strategies, and support more confident decision-making across the R&D lifecycle.
The award recognizes BostonGene’s immune-centric foundation model, which combines multimodal biological data with advanced AI to generate a comprehensive understanding of tumor and immune system dynamics. By treating the immune system as an active driver of therapeutic response rather than a secondary biomarker, the platform enables biopharma teams to better understand patient heterogeneity, refine development strategies, and evaluate critical decisions throughout clinical development.
“In an industry where clear performance metrics matter most,” said Russ Fordyce, Chief Recognition Officer of the Business Intelligence Group. “BostonGene stood out as an Outstanding Organization because its work reflects exactly where the market is headed: practical, biologically grounded AI that delivers immense, measurable value across multiple categories.”
To achieve this level of biological and clinical insight, BostonGene’s platform was trained on billions of data points, including a specialized immune system profiling dataset comprising more than 18,000 blood samples. The underlying methodologies have been validated across independent cohorts, presented at major scientific conferences including ASCO, AACR, ASH, SITC, and ESMO, and published in high-impact peer-reviewed journals including Cancer Cell, Blood and Nature.
“This recognition reflects the depth of science our team has built and the trust our clinical and biopharma partners place in us,” said Nathan Fowler, MD, Chief Medical Officer at BostonGene. “Our goal is to help pharmaceutical companies make better development decisions by combining multimodal biology, deep tumor and immune system understanding, and biologically grounded AI. By providing a clearer view of patient biology, we help identify opportunities earlier, reduce development risk, and increase the probability of clinical success.”
About BostonGene Corporation
BostonGene powers an AI model of tumor and immune biology to deliver disease-level insights and enable precision decision-making across oncology and immune-mediated diseases, spanning drug development and clinical care. By integrating multimodal data, including genomic, transcriptomic, immune, and clinical signals, BostonGene generates biologically grounded intelligence to optimize patient selection, trial design, and therapeutic strategy. This creates a scalable AI decision layer that improves development outcomes and clinical management. BostonGene partners with leading biopharmaceutical organizations and academic institutions to accelerate the delivery of precision therapies while continuously expanding its capabilities across new diseases and complex biological systems. For more information, visit www.BostonGene.com.
“BostonGene stood out as an Outstanding Organization because its work reflects exactly where the market is headed: practical, biologically grounded AI that delivers immense, measurable value across multiple categories.”
Contacts
BostonGene
Erin Keleher
+1-617-283-2285
Erin.Keleher@BostonGene.com
If you believe this article contains misleading, harmful, or spam content, please let us know.
